Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Luma Health Co vs Silhouette MD

Luma Health Co
Graded #62

Higher grade

vs+5.3999999999999915
Silhouette MD
Graded #129

Lower grade

The verdict

Luma Health Co takes it — 74.8/100 to 69.4/100.

Luma Health Co grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Luma Health Co is a nurse-practitioner-led virtual weight-loss and wellness clinic founded by Tiffani McKnight, FNP-C.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueSilhouette MD +6
68
74
Dose & formulationSilhouette MD +6
69
75
Clinical oversightLuma Health Co +6
83
77
Labs & monitoringLuma Health Co +43
97
54
FulfillmentLuma Health Co +3
70
67
Contract termsEven
55
55
Luma Health Co · left barSilhouette MD · right bar

The numbers

MetricLuma Health CoSilhouette MD
WeighScore74.8/10069.4/100
GradeCC
Scorecard rank#62#129
Semaglutide$120/mo (plus a separate fee, compounded)$149/mo (compounded)
Tirzepatide$180/mo (compounded)$299/mo (compounded)
Coverage30 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Luma Health Co

Graded #62 · C

Strengths

  • Transparent, competitive pricing published up front — compounded semaglutide from $120/mo, tirzepatide from $180/mo, retatrutide from $170/mo
  • No subscription, monthly fee or membership — a direct-to-patient model where you pay per medication, and follow-up visits are free
  • Free initial consults for first responders, law enforcement, military, nurses and teachers ($0), and $25 for other healthcare workers
  • Founded and led by a named family nurse practitioner (Tiffani McKnight, FNP-C) licensed across 30 states/DC, with HIPAA-compliant virtual visits
  • HSA/FSA funds and financing accepted, with itemized invoices for HSA/FSA submission

Where it loses points

  • Offers compounded retatrutide (labeled "RTT/GLP-3"), an investigational triple agonist not FDA-approved — a higher-risk, less-studied option
  • Compounded medications only — no brand-name Wegovy, Zepbound or Ozempic — and compounded GLP-1s aren't FDA-reviewed or approved
  • No LegitScript certification shown and no compounding-pharmacy partner named, so the dispensing pharmacy can't be independently verified
  • Small, newly established founder-led practice with a thin website and limited public track record or third-party reviews
  • Medication prices are "starting at" and billed on top of a one-time consult fee, so the true first-month cost runs higher than the headline
Silhouette MD

Graded #129 · C

Strengths

  • Compounded semaglutide and tirzepatide in both injectable and oral formulations
  • Concierge-level support — monitoring, expert guidance, and check-ins included on every plan
  • Transparent, published pricing starting at $149/mo for semaglutide injection
  • Prescriptions issued and fulfilled by licensed clinical partner OpenLoop Health

Where it loses points

  • Tirzepatide ($299/mo) and oral options ($263–$325/mo) priced above many compounded competitors
  • State availability not published
  • Newer brand with limited independent review history
  • Medications are compounded, not FDA-approved brand-name

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard